Survanta versus BLES in neonatal respiratory distress syndrome: A retrospective two-center study in Libya
Kamila A. Essamilghi, Khadiga I. A. Shreef, Salm R. Keshba, Ayah A. Altawati, Nissreen Z. Imbark, Nadia A. M. Eldarogi, Ali I. A. Almisurati, Eman A. Jahan
Abstract
Surfactant replacement therapy is an established component of the management of neonatal respiratory distress syndrome. In Libyan tertiary neonatal intensive care units, Survanta (Beractant) and bovine lipid extract surfactant (BLES) are commonly used natural bovine surfactant preparations. To compare clinical outcomes, respiratory support requirements, selected complications, and duration of hospitalization among neonates treated with Survanta or BLES at two Libyan medical centers. This retrospective comparative cohort study was conducted at Benghazi Medical Center and Misurata Medical Center (August 2024 to August 2026). A total of 610 medical records of neonates who received surfactant therapy were reviewed. After excluding 102 records because of incomplete documentation, 508 neonates were included in the final analysis: 228 in the Survanta group and 280 in the BLES group. Data included demographic characteristics, baseline arterial blood gas findings, post-treatment respiratory support, selected procedural and clinical complications, duration of hospitalization, and survival outcomes. Hyaline membrane disease was the most common indication for surfactant therapy, accounting for 88.8% of the cases. There are no differences were observed between the Survanta and BLES groups in mechanical ventilation requirement, CPAP requirement, pneumothorax, bronchopulmonary dysplasia, or survival outcome. Compared with the Survanta group, a greater proportion of neonates in the BLES group had a NICU stay of seven days or longer (66.7% vs. 33.3%, p=0.002), a total hospital stay of 7 - 14 days (67.5% vs. 32.5%, p=0.001), and nosocomial sepsis (60.2% vs. 39.8%, p=0.019). Procedural bradycardia (54.1% vs. 45.9%, p=0.001), oxygen desaturation (50.2% vs. 49.8%, p=0.018), and intraventricular hemorrhage (63.6% vs. 36.4%, p=0.025) were more frequently observed in the Survanta group, whereas post-instillation systemic hypotension was more frequently observed in the BLES group (61.3% vs. 38.7%, p=0.001). Thus, Survanta and BLES showed no differences in the primary respiratory and survival outcomes examined. Differences were observed in the duration of hospitalization, nosocomial sepsis, and selected procedural and clinical complications.
Keywords
References
- Donn SM, Dalton J. Surfactant replacement therapy in the neonate: Beyond respiratory distress syndrome. Respiratory Care. 2009; 54(9): 1203-1208. PMID: 19712497.
- Sweet DG, Carnielli VP, Greisen G, Hallman M, Klebermass-Schrehof K, Ozek E, et al. European consensus guidelines on the management of respiratory distress syndrome: 2022 update. Neonatology. 2023; 120(1): 3-23. doi: 10.1159/000528914
- Lam BCC, Ng YK, Wong KY. Randomized trial comparing two natural surfactants (Survanta vs. bLES) for treatment of neonatal respiratory distress syndrome. Pediatric Pulmonology. 2005; 39(1): 64-69. doi: 10.1002/ ppul.20125
- Sabzevari F, Eslamian M, Karami Robati F, Bahmanbijari B, Daei Parizi Z, Jamali Z. Comparison of the efficacy of two natural surfactants (BERAKSURF and BLES) in the treatment of respiratory distress syndrome among preterm neonates. BioMedical Center Pediatrics. 2023; 23(1): 608. doi: 10.1186/s12887-023-04406-2
- Ng EH, Shah V. Guidelines for surfactant replacement therapy in neonates. Pediatrics and Child Health. 2021; 26(1): 35-41. doi: 10.1093/pch/pxaa116
- Izadi R, Shojaei P, Haqbin A, Habibolahi A, Sadeghi-Moghaddam P. Comparing the clinical and economic efficiency of four natural surfactants in treating infants with respiratory distress syndrome. PLoS ONE. 2023; 18(6): e0286997. doi: 10.1371/journal.pone.0286997
- Macooie AA, Fakour Z, Roanaghi P. Comparative evaluation of the effects of BLES and Survanta on treatment of respiratory distress syndrome in newborns. Journal of Family Medicine and Primary Care. 2018; 7(5): 1063-1067. doi: 10.4103/jfmpc.jfmpc_188_17
- Abdel-Latif ME, Osborn DA. Pharyngeal instillation of surfactant before the first breath for prevention of morbidity and mortality in preterm infants at risk of respiratory distress syndrome. Cochrane Database of Systematic Reviews. 2011; 3: CD008311. doi:10.1002/14651858.CD008311.pub2
- Mussavi M, Mirnia K, Asadollahi K. Comparison of the efficacy of three natural surfactants (Curosurf, Survanta, and Alveofact) in the treatment of respiratory distress syndrome among neonates: a randomized controlled trial. Iranian Journal of Pediatrics. 2016; 26(5): e5743. doi: 10.5812/ijp.5743
- Ramanathan R. Surfactant therapy in preterm infants with respiratory distress syndrome and in near-term or term newborns with acute RDS. Journal of Perinatology. 2006; 26 (Suppl 1): S51-S56. doi: 10.1038/sj.jp.7211474
- Ramanathan R. Animal-derived surfactants: where are we? The evidence from randomized, controlled clinical trials. Journal of Perinatology. 2009; 29(Suppl 2): S38-S43. doi: 10.1038/jp.2009.31
- Ramanathan R, Sekar KC, Rasmussen L, Bhatia J, Soll RF. Heliox delivery and surfactant therapy in premature infants with RDS. Pediatrics. 2012; 130(4): e982-e990. doi: Nil.
- Alouzi NA, Hashad NS, Yamane MA. Drug utilization pattern in the NICU: A World Health Organization-Anatomical Therapeutic Chemical Classification-based cross-sectional study. Mediterranean Journal of Pharmacy and Pharmaceutical Sciences. 2025; 5(3): 75-82. doi: 0.5281/zenodo.16970145
- Kurt A, Ulusoy CO, Kurt DS, Özkan S, Dereli ML, Kından A, Çelik ÖY, Uzlu SE, Çelen Ş. Impact of antenatal corticosteroid therapy on neonatal respiratory outcomes in late preterm births. BioMedical Center Pediatrics. 2025; 25(1): 595. doi: 10.1186/s12887-025-05925-w
Submitted date:
07/30/2026
Reviewed date:
09/07/2026
Accepted date:
09/11/2026
Publication date:
09/13/2026
